Modified conditioning regimen with chidamide and high-dose rituximab for triple-hit lymphoma.
Junnan KangYizhuo ZhangSa DingKalbinur YashengYueyang LiYong YuYafei WangChen TianPublished in: Journal of cellular and molecular medicine (2021)
Triple-hit lymphoma (THL), which is classified into high-grade B-cell lymphoma with rearrangements of MYC, BCL2 and BCL6, presents aggressive biological behaviour. High-dose chemotherapy followed by autologous hematopoietic stem cell transplantation (auto-HSCT) is considered to be one of the recommended treatment options. Here, we reported 3 THL patients received carmustine, etoposide, cytarabine and cyclophosphamide (BEAC) combined with chidamide and high-dose rituximab conditioning regimen and found that this conditioning showed good efficacy and tolerance without increase of adverse events.
Keyphrases
- high dose
- diffuse large b cell lymphoma
- stem cell transplantation
- low dose
- high grade
- end stage renal disease
- newly diagnosed
- ejection fraction
- chronic kidney disease
- acute myeloid leukemia
- peritoneal dialysis
- prognostic factors
- low grade
- bone marrow
- hodgkin lymphoma
- transcription factor
- patient reported outcomes
- squamous cell carcinoma
- cell therapy
- platelet rich plasma